Skip to main content
. 2015 Apr 11;41(6):975–984. doi: 10.1007/s00134-015-3751-z

Table 1.

Patient characteristics at baseline (before randomization)

PMX-treated group (n = 119) Standard treatment (n = 113)
Age (years) 71.5 (19–90) 72 (39–94)
Male–female ratio, no. (%) 72 (60)–47 (40) 62 (55)–51 (45)
SAPS2 57 (25–107) 59 (21–116)
SOFA score 10 (3–15) 10 (5–14)
McCabe 1, no. (%) 73 (61) 71 (63)
McCabe 2, no. (%) 45 (38) 38 (34)
McCabe 3, no. (%) 1 (1) 4 (4)
Body weight (kg) 74 (43–185) 78 (40–137)
Pre-existing conditions, no. (%)
 Hypertension 69 (58) 63 (56)
 Cardiac failure 13 (11) 13 (12)
 Diabetes 24 (20) 20 (18)
 Chronic renal disorders 2 3
 Cancer or hematological malignancy
  Remission 21 (18) 23 (20)
  Evolutive 14 (12) 10 (9)
Heart rate (beat/min) 112 (61–177) 105 (60–168)
Systolic arterial pressure (mmHg) 90 (45–150) 93 (45–183)
Diastolic arterial pressure (mmHg) 50 (26–80) 50 (15–95)
Mean arterial pressure (mmHg) 64 (31–93) 65 (28–96)
Leukocytes count (103/mL) 8.9 (0.5–43.3) 8.9 (0.3–39.6)
Platelets count (103/mL) 216 (35–931) 217 (30–700)
INR 1.64 (1.10–4.90) 1.70 (1.10–3.10)
Plasma creatinine (µmol/L) 133 (38–570) 133 (30–464)
Bilirubin (µmol/L) 15 (2–142) 15 (2–132)
Lactates (mmol/L) 2.9 (0.7–13.0) 3.1 (0.5–13.0)
Plasma IL-6 (pg/mL) 2,146 (107–9,717) 1,927 (540–9,757)
Mechanical ventilation, no. (%) 117 (98) 110 (97)
pH 7.29 (6.91–7.50) 7.28 (6.86–7.47)
PaO2/FiO2 219 (46–573) 197 (63–659)
Norepinephrine infusion, no. (%) 119 (100) 113 (100)
Norepinephrine infusion rate (µg/kg/min) 0.44 (0.04–5.00) 0.41 (0.30–11.40)
Epinephrine infusion, no. (%) 1 (1) 7 (6)
Dobutamine infusion, no. (%) 6 (3) 2 (2)
Fluid therapy before randomization (mL) 4,497 (354–14,723) 4,000 (500–13,232)

Values expressed as median with minimum–maximum (min–max) or in number and percentage (%). Numerical values are expressed as median (min–max) except for IL-6 median (interquartile range)

SAPS simplified acute physiologic score, INR international normalized ratio